Testing Status of Salicylazosulfapyridine 11177-H
CASRN: 599-79-1
Formula: C18-H14-N4-O5-S
Synonyms/Common Names
- 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azobenzoic acid (9CI)
- SASP
- Sulfasalazine
Short-Term Toxicity
- 14-Day (Gavage)
(C61552)
Completed
- Rats: F344/N; Mice: B6C3F1
- 13 weeks (Gavage)
(C61552)
Completed
- Rats: F344/N; Mice: B6C3F1
- Dose: R: 0, 84, 169, OR 337 M: 0, 675, 1350, OR 2700 MG/KG.
Long-Term Carcinogenicity
- 2 & 3 years (Gavage)
(C61552B)
Completed
- TR-457 (NIH Number: 97-3373)
(Peer Review Approval 06/20/1995A )
Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CASRN 599-79-1) in F344 Rats and B6C3F1 Mice (Gavage Studies) - Rats: F344/N; Mice: B6C3F1
- Carcinogenesis Results
- Male Rats Some Evidence
- Female Rats Some Evidence
- Male Mice Clear Evidence
- Female Mice Clear Evidence
- Dose: R: 84, 168, OR 337.5 MG/KG; 70/GROUP M: 675, 1350, OR 2700 MG/KG; 60/GROUP.
- TR-457 (NIH Number: 97-3373)
(Peer Review Approval 06/20/1995A )
Special Studies
- Toxicokinetic Study (Gavage)
(S0312)
Completed
- Citation: Zheng W, Winter SM, Mayersohn M, Bishop JB, Sipes IG. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. Drug Metab Dispos. 1993 Nov-Dec;21(6):1091-7.Pubmed Abstract
- Male Rats: F344/N; Male and Female Rats: F344/N; Male and Female Mice: B6C3F1
- Dose: MICE:675, 1350, 2700 MG/KG (BOTH SEXES).
Genetic Toxicology
- Chromosome Aberrations
(459882)
Completed
- Citation: Bishop, J.B., Witt, K.L., Gulati, D.K., and MacGregor, J.T. Evaluation of the mutagenicity of the Anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis Vol. 5 (1990) 549-554
- Mice
- Negative (Nonstandard Protocol)
- Chromosome Aberrations
(724355)
Completed
- Mice
- Negative (Nonstandard Protocol)
- Chromosome Aberrations
(A93691)
Completed
- Mice
- Negative (Nonstandard Protocol)
- In Vitro Cytogenetics (CA/SCE)
(291257)
Completed
- Citation: Bishop, J.B., Witt, K.L., Gulati, D.K., and MacGregor, J.T. Evaluation of the mutagenicity of the Anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis Vol. 5 (1990) 549-554
- Sister Chromatid Exchange Negative
- Chromosome Aberrations Negative
- Micronucleus
(107236)
Completed
- Rats: Fischer 344
- Male Equivocal
- Micronucleus
(459882)
Completed
- Citation: Bishop, J.B., Witt, K.L., Gulati, D.K., and MacGregor, J.T. Evaluation of the mutagenicity of the Anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis Vol. 5 (1990) 549-554
- Mice: B6C3F1
- Male Negative
- Micronucleus
(724355)
Completed
- Mice: B6C3F1
- Male Not a Valid Test
- Micronucleus
(A66124)
Completed
- Citation: Bishop, J.B., Witt, K.L., Gulati, D.K., and MacGregor, J.T. Evaluation of the mutagenicity of the Anti-inflammatory drug salicylazosulfapyridine (SASP). Mutagenesis Vol. 5 (1990) 549-554
- Citation: Witt, K.L., Knapton, A., Wehr, C.M., Hook, G.J., Mirsalis, J., Shelby, M.D., and MacGregor, J.T. Micronucleated Erythrocyte Frequency in Peripheral Blood of B6C3F1 Mice from Short-Term, Prechronic, and Chronic Studies of the NTP Carcinogenesis Bioassay Program. Environ. Molec. Mutagen. Vol. 36 (2000) 163-194
- Mice: B6C3F1
- Male Positive
- Female Positive
- Micronucleus
(A72306)
Completed
- Mice: B6C3F1
- Male Positive
- Micronucleus
(A93691)
Completed
- Mice: B6C3F1
- Male Positive (Nonstandard Protocol)
- Female Positive
- Salmonella
(031562)
Completed
- Citation: Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., and Mortelmans, K. Salmonella mutagenicity tests. IV. Results from the testing of 300 chemicals Environ. Molec. Mutagen. Vol. 11 (Suppl 12) (1988) 1-158
- Negative
- Sister Chromatid Exchanges
(724355)
Completed
- Mice
- Sister Chromatid Negative (Nonstandard Protocol)
Organ Systems Toxicity
- greater than 120 days Continuous Breeding (Legacy) (Gavage)
(RACB90002)
Completed
- Rats: Sprague Dawley
- Dose: 0, 100, 200, 400, 600, 800 MG/KG; 0, 100, 200, 400 MG/KG/DAY; 0, 100, 200, 400 MG/KG/DAY; 0, 100, 200, 400 MG/KG/DAY.